Er werd geen verschil waargenomen tussen intraveneuze en subcutane wekelijks toegediende dosis. ###>Data from 809 patients receiving Aranesp in European clinical studies were analysed to assess the dose required to maintain haemoglobin; no difference was observed between the average weekly dose administered via the intravenous or subcutaneous routes of injection.